ArticleJACC. Case reports2026
Fatal Yellow Oleander Poisoning From a Weight-Loss Seed Product Requiring Venoarterial Extracorporeal Membrane Oxygenation.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundYellow oleander (Cascabela thevetia) seeds marketed as "slimming seeds" in unregulated weight-loss products can cause life-threatening digitalis-like toxicity. CASE SUMMARY: A 47-year-old woman accidentally ingested approximately 50 yellow oleander seeds sold as a weight-loss supplement. She developed gastrointestinal symptoms, atrial tachyarrhythmias with high-grade atrioventricular block, hyperkalemia, and metabolic acidosis. She received activated charcoal and digoxin immune Fab with transient improvement. Twelve hours later, evolving acute kidney injury led to recurrent refractory ventricular fibrillation. Despite extracorporeal cardiopulmonary resuscitation and venoarterial extracorporeal membrane oxygenation, she died. DISCUSSION: This case highlights delayed recurrence after a large plant cardiac glycoside ingestion, limitations of total serum digoxin assays after Fab administration, and the risk of catecholaminergic agents precipitating ventricular arrhythmias. TAKE-HOME MESSAGES: Early digoxin immune Fab guided by electrocardiography and potassium levels-rather than total digoxin levels-is critical. Delayed recurrence should be anticipated with large ingestions and renal impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.